Uroprotectants Market Set to Register a Steady Revenue CAGR of 5.2% by 2031 | Growth Plus Reports


Newark, New Castle, USA, April 26, 2023 (GLOBE NEWSWIRE) — In accordance with the most recent analysis by Growth Plus Reports, the global market for uroprotectants is expected to expand at a revenue CAGR of 5.2% during the forecast period 2023-2031.

The global market for uroprotectants was analyzed and is expected to show significant revenue growth during the forecast period. Uroprotectants are a class of medications intended to prevent or lessen the severity of hemorrhagic cystitis, particularly in patients taking chemotherapy treatments that can induce it. Mesna is one of the most regularly utilized uroprotectants for this reason.

Key Takeaways: 


  • The rising prevalence of cancer and chemotherapy is driving the market revenue share.
  • The rising drug advancements with the incorporation of nanoparticles are driving market revenue growth.
  • Collaboration among pharmaceutical companies is leading to the introduction of novel drugs.

Request a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/uroprotectants-market/8797

                                           Uroprotectants Market Scope

Report Attribute Details
CAGR 5.2%
Base Year for Estimation 2020
Forecast Period 2021 to 2031
Historical Year 2021
Segments Covered Indication, Route of Administration, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Recent Development in the Global Uroprotectants Market: 

  • In May 2022, The Research Group for Hefei Institutes of Physical Science (HFIPS) recently proposed a new technique for the optical detection of Mesna. The scientists used a newly constructed portable sensing device with an upconversion-based nanosensor to analyze quantitative Mesna in real-time situations.

Competitive Landscape

List of the top market players operating in the global market for uroprotectants: 

  • Athenex Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sagent Pharmaceuticals
  • Baxter International Inc.
  • Fresenius Kabi AG

Market Drivers and Restraints: 

The global uroprotectants market revenue is driven by the availability of innovative medications, a strong pipeline, the rise in urothelial cancer incidence due to an aging population, a disorganized lifestyle, and expanding public awareness.

However, side effects are caused by these drugs. Stringent regulations and high costs of drugs are expected to restrain market revenue growth of the global uroprotectants. 

Market Segmentation: 

Segmentation By Indications

Based on indications, the global uroprotectants market is segmented into blood cancer, gynecological cancer, bone cancer, bladder cancer, and others. Due to the rising prevalence and prevention of chemotherapy-associated hemorrhagic cystitis, the bladder cancer segment accounts for the largest market revenue share. 

Segmentation By Route of Administration

Based on the route of administration, the global uroprotectants market is segmented into oral and intravenous. The intravenous (IV) segment accounts for the largest revenue share due to being one of the most common routes of administration for chemotherapy due to its quick action.

Regional Growth Dynamics

Based on the region, the global uroprotectants market is segmented into North America, Asia Pacific, Latin America, Europe, and the Middle East & Africa. Due to the rising prevalence of cancer leading to the high demand for uroprotectents, North America accounts for the largest revenue share in the global market.

Request for Customization – https://www.growthplusreports.com/inquiry/request-sample/uroprotectants-market/8797

Report Coverage 

Growth Plus Reports studied the global market for uroprotectants in-depth. Basic market features, important investment sectors, analyses of regional growth, revenue projections, rival market participants, and mergers and acquisitions were all examined.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources 
      1. Secondary Sources
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursement Scenario
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Blood Cancer
    2. Gynecological Cancer
    3. Bone Cancer
    4. Bladder Cancer
    5. Others
    1. Oral 
    2. Intravenous


Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8797


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse Latest Healthcare Related Reports:

Lesch Nyhan Syndrome Therapeutics Market by Drug Class (Hypouricemic Agents, Benzodiazepines), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies) – Global Outlook & Forecast 2023-2031

Hepatic Encephalopathy Treatment Market by Drug Class (Laxatives and Antibiotics), Route of Administration (Oral, Intravenous, and Rectal), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook and Forecast 2023-2031

Medical Tricorder Market by Type (Wireless, USB Camera), Application (Diagnosis, Monitoring), End User (Hospitals and Clinics, Homecare Settings) – Global Outlook & Forecast 2023-2031

Livestock Diagnostics Market by Product (Consumables, Hardware, Software), Technology (Immunodiagnostics, Molecular Diagnostics), Animal Type (Ruminants, Swine, Poultry), End User (Reference Laboratories, Diagnostic Hospitals & Clinics) – Global Outlook & Forecast 2023-2031

Ulcerative Colitis Market by Type (Ulcerative Proctitis, Proctosigmoiditis), Drug Class (Immunomodulators, Anti-inflammatory Drugs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.